Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.
Obodence (denosumab) has been authorised in the EU for osteoporosis and related bone resorption indications.
-
EMA approval · 2026-07-14EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
The EMA has authorised Bildyos (denosumab) by Sciencepharma Sp. z o.o. for bone resorption disorders including osteoporosis, including postm…
-
EMA approval · 2026-04-24EMA Authorised: Vysribli (previously Denosumab Intas) (denosumab) — Intas Third Party Sales 2005 S.L.
EMA authorised Vysribli (denosumab) for osteoporosis indications, including postmenopausal osteoporosis, with MAH Intas Third Party Sales 20…
-
EMA approval · 2026-04-20EMA Authorised: Aclasta (zoledronic acid) — Sandoz Pharmaceuticals d.d.
The EMA authorised Sandoz's Aclasta (zoledronic acid) for osteoporosis indications, including postmenopausal osteoporosis and Paget disease …
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Combined Anabolic Therapy [Phase 4]
Phase 4 clinical trial update for Combined Anabolic Therapy targeting osteoporosis in postmenopausal patients. Recruitment is ongoing.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2026-04-15Clinical Trial Update: Anabolic Therapy in Postmenopausal Osteoporosis [Phase 4]
This clinical trial update notes a Phase 4 anabolic-therapy study for postmenopausal osteoporosis that is currently active but not recruitin…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women [Phase 2]
Phase 2 clinical trial evaluating everolimus and/or exercise to prevent bone loss in postmenopausal women; currently active but not recruiti…
-
EMA approval · 2026-03-20EMA Authorised: Evfraxy (denosumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Evfraxy (denosumab) as a biosimilar; it is approved for bone resorption disorders including osteoporosis and postmenopausal o…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women [NA]
A completed clinical trial investigated whether probiotic strains affect bone mineral density in postmenopausal women.
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Resveratrol for the Prevention of Bone Loss in Postmenopausal Women [NA]
A completed clinical trial evaluating resveratrol for prevention of bone loss in postmenopausal women with low bone mass.
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes [Phase 2]
Phase 2 clinical trial evaluating romosozumab effects on bone density, muscle mass, and spine surgery outcomes in osteoporosis, with status …
-
EMA approval · 2026-03-04EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
The European Medicines Agency authorised Kefdensis, a denosumab medicine by STADA Arzneimittel AG, for osteoporosis indications including po…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: COMPASS - COpenhagen MenoPAuSe Study [Phase 2]
Phase 2 clinical trial update for the COMPASS Copenhagen Menopause Study investigating postmenopausal osteoporosis and bone markers; recruit…
-
EMA approval · 2026-02-26EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence, a denosumab product from Fresenius Kabi Deutschland GmbH, for osteoporosis including postmenopausal osteoporosis.…
-
EMA approval · 2026-02-24EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH
The European Medicines Agency has authorised Acvybra (denosumab) from Reddy Holding GmbH for osteoporosis-related conditions, including post…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Romosozumab Use to Build Skeletal Integrity [Phase 4]
Phase 4 trial update shows romosozumab for enhancing skeletal integrity in osteoporosis (including postmenopausal osteoporosis and osteoporo…
-
EMA approval · 2026-02-12EMA Authorised: Fosavance (alendronic acid;colecalciferol) — Organon N.V.
EMA authorised Fosavance (alendronic acid and colecalciferol) by Organon N.V. for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-02-12EMA Authorised: Adrovance (colecalciferol;alendronic acid (as sodium trihydrate)) — Organon N.V.
The European Medicines Agency authorised Adrovance, a fixed-dose combination of colecalciferol (vitamin D3) and alendronic acid (as sodium t…
-
EMA approval · 2026-02-12EMA Authorised: Vantavo (previously Alendronate sodium and colecalciferol, MSD) (alendronic acid;colecalciferol) — Organon N.V.
EMA authorised the medication Vantavo, a fixed combination of alendronic acid and colecalciferol, for postmenopausal osteoporosis, with Orga…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation [Phase 4]
Phase 4 clinical trial comparing ibandronate to zoledronic acid after denosumab discontinuation in postmenopausal osteoporosis and osteopeni…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® [Phase 3]
A phase 3 trial comparing a biosimilar denosumab to Prolia in postmenopausal osteoporosis has completed with results posted.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture [Phase 1]
Phase 1 study evaluating intravenous HMM910, a human mesenchymal stem cell therapy, in postmenopausal women with osteoporosis at high fractu…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) [Phase 2]
A Phase 2 clinical trial (ARTEMIS) evaluating the efficacy of AGA2118 in postmenopausal osteoporosis is currently active but not recruiting.
-
EMA approval · 2026-02-06EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
EMA authorised Bildyos, a denosumab medicine by Sciencepharma Sp. z o.o., for osteoporosis and postmenopausal osteoporosis related to bone r…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for ibandronate sodium by Macleods Pharmaceuticals Limited.